A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Data on the effectiveness of antipsychotics in the early phase of schizophrenia are limited. The authors examined the risk of rehospitalization and drug discontinuation in a nationwide cohort of 2,588 consecutive patients hospitalized for the first time with a diagnosis of schizophrenia between 2000 and 2007 in Finland. METHOD: The authors linked national databases of hospitalization, mortality, and antipsychotic prescriptions and computed hazard ratios, adjusting for the effects of sociodemographic and clinical variables, the temporal sequence of the antipsychotics used, and the choice of the initial antipsychotic for each patient. RESULTS: Of 2,588 patients, 1,507 (58.2%) collected a prescription for an antipsychotic during the first 30 days after hospital discharge, and 1,182 (45.7%, 95% confidence interval [CI]=43.7-47.6) continued their initial treatment for 30 days or longer. In a pairwise comparison between depot injections and their equivalent oral formulations, the risk of rehospitalization for patients receiving depot medications was about one-third of that for patients receiving oral medications (adjusted hazard ratio=0.36, 95% CI=0.17-0.75). Compared with oral risperidone, clozapine (adjusted hazard ratio=0.48, 95% CI=0.31-0.76) and olanzapine (adjusted hazard ratio=0.54, 95% CI=0.40-0.73) were each associated with a significantly lower rehospitalization risk. Use of any antipsychotic compared with no antipsychotic was associated with lower mortality (adjusted hazard ratio=0.45, 95% CI=0.31-0.67). CONCLUSIONS: In Finland, only a minority of patients adhere to their initial antipsychotic during the first 60 days after discharge from their first hospitalization for schizophrenia. Use of depot antipsychotics was associated with a significantly lower risk of rehospitalization than use of oral formulations of the same compounds. Among oral antipsychotics, clozapine and olanzapine were associated with more favorable outcomes. Use of any antipsychotic was associated with lower mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 2×
“2% of patients did not regularly take medication as prescribed (8), that prescription completion rates ranged from 28% to 85% (9), and that irregular medication use rates ranged from 31% to 62% (9).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Self-citationRobinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Self-citationMedication adherence of individuals with a first episode of psychosis
Coldham, E. L., Addington, J., & Addington, D. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02437.x · Cited by 413
Research works printed but not linked: 4
- National Institute for Health and Clinical Excellence (NICE), 2009, Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82)
- Young JL, 1986, Bull Am Acad Psychiatry Law, 14, 105
- Young JL, 1999, J Am Acad Psychiatry Law, 27, 426
- 10.1176/ps.2007.58.4.482 · doi:10.1176/ps.2007.58.4.482 · Paper page
Cited by
Items 201–300 of 618
Catalán, R., González-Rodríguez, A., Penadés, R., García‐Rizo, C., Bioque, M., Parellada, E., & Bernardo, M. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s63948 · Cited by 31
Strømme, M. F., Mellesdal, L., Bartz-Johannessen, C. A., Kroken, R. A., Krogenes, M. L., Mehlum, L. I., & Johnsen, E. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.07.009 · Cited by 27
Solmi, M., Taipale, H. T., Torniainen‐Holm, M., Tanskanen, A. J., Mittendorfer‐Rutz, E., Correll, C. U., & Tiihonen, J. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.21121189 · Cited by 30
Self-citationPřikryl, R., Kučerová, H. P., Vrzalová, M., & Češková, E. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/764769 · Cited by 26
Productivity loss of caregivers of schizophrenia patients: a cross-sectional survey in Japan
Sruamsiri, R., Mori, Y., & Mahlich, J. (2018) · Journal of Mental Health · doi:10.1080/09638237.2018.1466048 · Cited by 28
Long-Acting Injectable Antipsychotics: An Underutilized Treatment Option
Heres, S. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14com09541 · Cited by 25
Caplan, B., Zimmet, S. V., Meyer, E. C., Friedman‐Yakoobian, M. S., Monteleone, T., Leung, Y. J., Guyer, M. E., Rood, L. L., Keshavan, M. S., & Seidman, L. J. (2013) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2012.10.009 · Cited by 27
Llorca, P., Bobes, J., Fleischhacker, W. W., Heres, S., Moore, N. D., Bent‐Ennakhil, N., Sapin, C., Loze, J.-Y., Nylander, A., & Patel, M. X. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.04.004 · Cited by 26
Self-citationMahlich, J., Olbrich, K., Wilk, A., Wimmer, A., & Wolff‐Menzler, C. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00990-8 · Cited by 30
Katona, L., Bitter, I., & Czobor, P. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01636-9 · Cited by 28
Kamat, S., Offord, S. J., Docherty, J. P., Lin, J., Eramo, A., Baker, R. A., Gutiérrez, B., & Karson, C. N. (2015) · Drugs in Context · doi:10.7573/dic.212267 · Cited by 26
Huang, K., Fang, C., Hsu, C., Wu, S., Juang, J. J., & Stewart, R. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117714047 · Cited by 24
Medrano, S., Abdel‐Baki, A., Stip, É., & Potvin, S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4577 · Cited by 27
Zhou, Y., Rosenheck, R., Mohamed, S., Ning, Y., & He, H. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.01.036 · Cited by 23
“Patients in the early stages of their illness have also been found in previous studies to be less compliant with treatment as they have less insight into their illness (Baloush-Kleinman et al., 2011; Tiihonen et al., 2011).”
ResultLi, G., Keenan, A., Daskiran, M., Mathews, M., Nuamah, I. F., Orman, C., Joshi, K., Singh, A., Godet, A., Pungor, K., et al. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s322880 · Cited by 25
Gentile, S. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12824 · Cited by 25
Samtani, C., Sheehan, J. J., Fu, Remmerie, Sliwa, & Alphs (2012) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s32735 · Cited by 26
Tiihonen, J., Tanskanen, A. J., Mittendorfer‐Rutz, E., Howes, O. D., Correll, C. U., Siskind, D. J., & Taipale, H. T. (2025) · World Psychiatry · doi:10.1002/wps.21316 · Cited by 25
Self-citationThe Neuroscience of Suicidal Behavior
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205 · Cited by 45
Mathews, M., Gopal, S., Singh, A., Nuamah, I. F., Pungor, K., Tan, W., Soares, B. G., Kim, E., & Savitz, A. J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s221242 · Cited by 23
Abdullah-Koolmees, H., Nawzad, S., Egberts, T. C. G., Vuyk, J., Gardarsdóttir, H., & Heerdink, E. R. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211027449 · Cited by 26
Stürup, A. E., Nordentoft, M., Jimenez‐Solem, E., Osler, M., Davy, J. W., Christensen, T. N., Speyer, H., Albert, N., & Hjorthøj, C. R. (2022) · Psychological Medicine · doi:10.1017/s0033291722002021 · Cited by 24
Köhler‐Forsberg, O., Horsdal, H. T., Legge, S. E., MacCabe, J. H., & Gasse, C. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000649 · Cited by 23
A critical appraisal of long acting injectable antipsychotics: Translating research to clinics
Sreeraj, V. S., Shivakumar, V., Rao, N. P., & Venkatasubramanian, G. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.03.018 · Cited by 23
Barriers to Utilizing Long-Acting Injectable Antipsychotic Medications
Getzen, H., Beasley, M., & D’Mello, D. A. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600104 · Cited by 22
Viala, A., Cornic, F., & Vacheron, M.-N. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/368687 · Cited by 27
The place of observational studies in assessing the effectiveness of depot antipsychotics
Haddad, P. M., Tiihonen, J., Haukka, J. K., Taylor, M., Patel, M. X., & Korhonen, P. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.022 · Cited by 22
Self-citationHata, T., Kanazawa, T., Hamada, T., Nishihara, M., Yoneda, H., Nakajima, M., & Katsumata, T. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.012 · Cited by 21
Checking the plausibility of psychiatrists׳ arguments for not prescribing depot medication
Hamann, J., Kissling, W., & Heres, S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.015 · Cited by 23
Ciudad, A., San, L., Bernardo, M., Olivares, J. M., Polavieja, P., Valladares, A., & Gilaberte, I. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.10.014 · Cited by 23
Bera, R. B. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13065su1c.07 · Cited by 21
Mahlich, J., Olbrich, K., Wilk, A., Wimmer, A., & Wolff‐Menzler, C. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00900-y · Cited by 25
Motor sequencing abnormalities are the trait marking neurological soft signs of schizophrenia
Ojagbemi, A., Esan, O., Emsley, R. A., & Gureje, O. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.06.028 · Cited by 21
Long-Acting Injectable Aripiprazole: How Might It Fit In Our Tool Box?
Gopalakrishna, G., Aggarwal, A., & Lauriello, J. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.goag.043013 · Cited by 22
Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
Parellada, E., Velligan, D. I., Emsley, R. A., & Kissling, W. (2012) · Schizophrenia Research and Treatment · doi:10.1155/2012/318535 · Cited by 24
Kane, J. M., Chen, A., Lim, S., Mychaskiw, M. A., Tian, M., Wang, Y., Suett, M., & Rubio, J. M. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000452 · Cited by 24
Psychiatric Patients’ Perceived Health Control and Reactance: Implications for Medication Adherence
Cuevas, C. D. L. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s417608 · Cited by 25
Kiviniemi, M. (2014) · Cited by 29
Patrón de uso de clozapina en España. Variabilidad e infraprescripción
Sanz-Fuentenebro, F. J., Uriarte, J. J. U., Dalmau, P. B., Molina, V., & Bernardo, M. (2018) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2018.02.005 · Cited by 22
Mace, S., Chak, O., Punny, S., Sedough-Abbasian, D., Vegad, C., & Taylor, D. M. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319860977 · Cited by 21
Abdel‐Baki, A., Medrano, S., Maranda, C., Ladouceur, M., Tahir, M. R., Stip, É., & Potvin, S. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000310 · Cited by 23
Schreiner, A., Svensson, A. E., Wapenaar, R., Chérubin, P., Princet, P., Serazetdinova, L., & Zink, M. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.902990 · Cited by 20
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02488-1 · Cited by 21
Portela, R., Wainberg, M. L., Castel, S., de Oliveira, H. N., & Ruas, C. M. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03794-6 · Cited by 26
The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria
James, B. O., Omoaregba, J. O., Okonoda, K. M., Otefe, E. U., & Patel, M. X. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312453158 · Cited by 19
Self-citationRoutine quality care assessment of schizophrenic disorders using information systems
Lora, A., Monzani, E., Ibrahim, B., Soranna, D., & Corrao, G. (2017) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzx019 · Cited by 20
Tungaraza, T. E., Ahmed, W., Chira, C., Turner, E., Mayaki, S., Nandhra, H. S., Edwards, T., & Farooq, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316683151 · Cited by 22
Tveito, M., Molden, E., Høiseth, G., Correll, C. U., & Smith, R. L. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02768-0 · Cited by 21
Real‐world effectiveness of antipsychotics
Tiihonen, J. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12641 · Cited by 19
Self-citationPeng, P., Li, J., Chen, Y., Li, M., Ma, F., Ji, S., Sun, S., & Tang, F. (2023) · BMJ Mental Health · doi:10.1136/bmjment-2022-300501 · Cited by 27
Telepsychiatry adoption across hospitals in the United States: a cross-sectional study
Li, Z., Harrison, S. E., Li, X., & Hung, P. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03180-8 · Cited by 19
Mahlich, J., Masamichi, N., & Yoshimichi, S. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s85514 · Cited by 18
Misdrahi, D., Bayle, F., Tessier, A., & Bouju, S. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s89748 · Cited by 23
Optimizing Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment
Morrissette, D. A., & Stahl, S. M. (2012) · CNS Spectrums · doi:10.1017/s1092852912000739 · Cited by 20
Prajapati, A. R., Wilson, J., Song, F., & Maidment, I. (2018) · Bipolar Disorders · doi:10.1111/bdi.12707 · Cited by 20
Psychotropic drugs and homicide: A prospective cohort study from Finland
Tiihonen, J., Lehti, M., Aaltonen, M., Kivivuori, J., Kautiainen, H., Virta, L. J., Hoti, F. J., Tanskanen, A. J., & Korhonen, P. (2015) · World Psychiatry · doi:10.1002/wps.20220 · Cited by 18
Self-citationClinician hesitation prior to clozapine initiation: is it justifiable?
Patel, M. X. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.112.114777 · Cited by 20
Self-citationIwata, N., Inagaki, A., Sano, H., Niidome, K., Kojima, Y., & Yamada, S. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01396-w · Cited by 18
Agid, O., Remington, G. J., Fung, C., Nightingale, N., Duclos, M., & Anger, G. J. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/07067437211055413 · Cited by 17
Gaudiano, B. A., Ellenberg, S., Johnson, J. E., Mueser, K. T., & Miller, I. W. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.09.017 · Cited by 20
Björkenstam, E., Björkenstam, C., Hjern, A., Reutfors, J., & Bodén, R. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.011 · Cited by 21
Generic atypical antipsychotic drugs in Belgium: their influence and implications
Godman, B., Bruyn, K. D., Miranda, J., Raschi, E., Bennie, M., Barbui, C., & Simoens, S. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.75 · Cited by 17
Lambert, M., Schöttle, D., Sengutta, M., Ruppelt, F., Rohenkohl, A. C., Luedecke, D., Nawara, L. A., Galling, B., Falk, A., Wittmann, L., et al. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12361 · Cited by 20
Schreiner, A., Caspi, A., Bergmans, P., Chérubin, P., Keim, S., Lara, E., Пінчук, І., Schuepbach, D., Suleman, S., & Hargarter, L. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4445-0 · Cited by 17
Kofman, T., Pourcine, F., Canouï‐Poitrine, F., Kamar, N., Malvezzi, P., François, H., Boutin, E., Audard, V., Lang, P., Martinez, F., et al. (2017) · Transplant International · doi:10.1111/tri.13078 · Cited by 17
Patel, M. X., Matonhodze, J., Baig, M. K., Taylor, D., Szmukler, G., & David, A. S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113486717 · Cited by 17
Self-citationInnovative Versorgungsmodelle für Menschen mit schizophrenen Erkrankungen
Lambert, M., Kraft, V., Rohenkohl, A. C., Ruppelt, F., Schröter, R., Lüdecke, D., Linschmann, B., Eich, S., Tlach, L., Lion, D., et al. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-018-2868-y · Cited by 21
Morton, N. K., & Zubek, D. (2013) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20130215-01 · Cited by 16
Li, P., Benson, C. J., Geng, Z., Seo, S., Patel, C. A., & Doshi, J. A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2189859 · Cited by 16
Köhler‐Forsberg, O., Petersen, L. V., Benros, M. E., Mors, O. N., & Gasse, C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1168400 · Cited by 16
Antipsychotiques à Action Prolongée: Révision de l’algorithme QAAPAPLE
Stip, É., Abdel‐Baki, A., Roy, M., Bloom, D., & Grignon, S. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719847193 · Cited by 22
Johnsen, E., & Kroken, R. A. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312462275 · Cited by 23
Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia
Potkin, S. G., & Preda, A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1114100 · Cited by 18
Antipsychotics and risk of natural death in patients with schizophrenia
Chen, Y., Yang, X., Qin, X., Yang, Q., Fan, H., Li, J., Song, X., Xu, S., Guo, W., Deng, W., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199748 · Cited by 21
Alphs, L. D., Brown, B., Turkoz, I., Baker, P. C., Fu, D., & Nuechterlein, K. H. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.02.019 · Cited by 16
Three-year outcomes and predictors for full recovery in patients with early-stage psychosis
Li, L., Rami, F. Z., Lee, B. M., Kim, W., Kim, S., Lee, B. J., Yu, J., Lee, K. Y., Won, S., Lee, S., et al. (2022) · Schizophrenia · doi:10.1038/s41537-022-00301-4 · Cited by 17
Fagiolini, A. M., de Bartolomeis, A., Vaggi, M., & Vampini, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s96214 · Cited by 16
Home Treatment – aufsuchende Behandlung im Hamburger Modell der Integrierten Versorgung
Schöttle, D., Ruppelt, F., Karow, A., & Lambert, M. (2014) · PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie · doi:10.1055/s-0034-1390424 · Cited by 21
Bozzatello, P., Bellino, S., Mancini, I., Sandei, L., Zanalda, E., & Rocca, P. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0734-1 · Cited by 16
Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz‐Marsá, M., García‐Portilla, M. P., Gutiérrez-Rojas, L., Olivares, J. M., Rico‐Villademoros, F., et al. (2019) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.03.004 · Cited by 25
Depot/Long Acting Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
Özgüven, H. D., & Kır, Y. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27480 · Cited by 19
Elowe, J., Ramain, J., Solida, A., Conus, P., & Golay, P. (2022) · European Psychiatry · doi:10.1192/j.eurpsy.2022.2305 · Cited by 17
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg
Citrome, L., Such, P., Yıldırım, M., Madera‐McDonough, J., Beckham, C., Zhang, Z., Larsen, F., & Harlin, M. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23m14873 · Cited by 14
Kane, J. M., Eshet, R., Harary, E., Tohami, O., Elgart, A., Knebel, H., Sharon, N. A., Suett, M., Franzenburg, K. R., Davis, G. L., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01102-2 · Cited by 14
Bidargaddi, N. P., Schrader, G. D., Myles, H., Schubert, K. O., van Kasteren, Y., Zhang, T., Bastiampillai, T. J., Roughead, E. E., & Strobel, J. E. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867421998800 · Cited by 13
Orsolini, L., Sceusa, F., Pompili, S., Mauro, A., Salvi, V., & Volpe, U. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1928634 · Cited by 15
Stürup, A. E., Hjorthøj, C. R., Albert, N., Dolmer, S., Birk, M., Ebdrup, B. H., Eplov, L. F., Jensen, H., Vernal, D. L., Speyer, H., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.910703 · Cited by 16
Park, M.-H., Han, C., Pae, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Fleischhacker, W. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.151 · Cited by 14
Controlled-release injectable microemulsions: recent advances and potential opportunities
Dubey, R. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.870151 · Cited by 15
Zhao, J., Li, L., Shi, J., Li, Y., Xu, X., Li, K., Zhang, L., Cai, S., Feng, Y., Zhuo, J., et al. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s131224 · Cited by 14
Si, T., Zhuo, J., Turkoz, I., Mathews, M., Tan, W., & Feng, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1401608 · Cited by 15
Bioque, M., & Bernardo, M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1515915 · Cited by 14
The pharmacological treatment of schizophrenia: how far have we come?
Rubio, J. M., & Kane, J. M. (2022) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.13 · Cited by 13
“66 Circumstances that increase the risk for nonadherence in schizophrenia are being at an earlier phase of treatment, 67,68 comorbid substance use, 69 social exclusion (i.e., homelessness), and high side effect burden.”
BackgroundEarly identification of treatment non-response in first-episode psychosis
Wold, K. F., Berg, A. O., Flaaten, C. B., Johnsen, E., Lagerberg, T. V., Romm, K. L., Simonsen, C., Ueland, T., Widing, L. H., Åsbø, G., et al. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.15 · Cited by 14
Ma, N., Zhang, L., Zhang, W., He, Y., Ye, C., & Li, X. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s413371 · Cited by 19
Kisely, S., Sawyer, E., Robinson, G., & Siskind, D. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.028 · Cited by 17
Ascher‐Svanum, H., Novick, D., Haro, J. M., Bertsch, J., McDonnell, D., & Detke, H. C. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-224 · Cited by 13
Kisely, S. R., Ligate, L., Roy, M., & Lavery, T. (2012) · Australasian Psychiatry · doi:10.1177/1039856212437257 · Cited by 13
Trends in the Use of Long-Acting Injectable Antipsychotics in the Province of Manitoba, Canada
Janzen, D., Bolton, J. M., Kuo, I. F., Leong, C., & Alessi‐Severini, S. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001148 · Cited by 15
Suicidal Behavior and Medication Adherence in Schizophrenic Patients
Warriach, Z. I., Sanchez‐Gonzalez, M. A., & Ferrer, G. F. (2021) · Cureus · doi:10.7759/cureus.12473 · Cited by 19
Metadata
- Authors
- Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P.
- Affiliations
- NHS Lothian (GB)
- Venue
- American Journal of Psychiatry
- Published
- 2011-06
- Volume
- 168
- Issue
- 6
- Pages
- 603-609
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2160096204
- Cited by
- 619
- References
- 28
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 21 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 32 · 2019: 42 · 2018: 51 · 2017: 55 · 2016: 39 · 2015: 52 · 2014: 42 · 2013: 61 · 2012: 44
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, long-acting injectable antipsychotics, oral antipsychotics, hospital readmission, treatment discontinuation, clozapine, olanzapine, risperidone, mortality, medication adherence, first hospitalization
- MeSH terms
- Administration, Oral, Adolescent, Adult, Delayed-Action Preparations, Drug Implants, Finland, Hospitalization, Humans, Injections, Middle Aged, Patient Readmission, Schizophrenia, Antipsychotic Agents, Cohort Studies, Treatment Outcome, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.